Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.

Summary

Multicenter, retrospective-prospective, real-world observational study, with the aim of evaluating tolerability and efficacy in a population of patients treated according to clinical practice outside of studies randomized.

Eligibility

Inclusion Criteria:

* Histological diagnosis of HER2 positive breast cancer;
* Presence of invasive residual disease on T or N after neoadjuvant chemotherapy including anti-HER2 agents
* Treatment with T-DM1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. Complementary radiotherapy will be allowed as per lines guide;
* Availability of adequate information regarding treatment with adjuvant T-DM1 in accordance with the objectives of the study;
* Written informed consent for the prospective part and, if possible, for the recruited patients retrospectively

Exclusion Criteria:

* Concomitant treatments with other biological agents;
* Absence of clinical data that allow the correct analysis of the primary and secondary objectives;
* Patients with a history of other malignant neoplasms;
* Contraindications to the use of T-DM

Conditions2

Browse More Trials